AI assistant
Sending…
PharmaCyte Biotech, Inc. — Director's Dealing 2023
Nov 28, 2023
35351_dirs_2023-11-28_04e86fd6-7dab-4610-b8c1-463fa6b4d2b3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: FEMASYS INC (FEMY)
CIK: 0001339005
Period of Report: 2023-11-21
Reporting Person: PharmaCyte Biotech, Inc. (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| 6.0% Senior Convertible Note due 2025 | $1.18 | 2025-11-21 | Common stock, par value $0.001 per share (4237288) | Direct | |
| Series A Warrants | $1.18 | 2028-11-21 | Common stock, par value $0.001 per share (4237288) | Direct | |
| Series B Warrants | $1.475 | 2024-11-21 | Common stock, par value $0.001 per share (4237288) | Direct |
More from PharmaCyte Biotech, Inc.
Interim / Quarterly Report
2026
Mar 17
Director's Dealing
2026
Jan 7
Director's Dealing
2026
Jan 7
Interim / Quarterly Report
2025
Dec 18
Regulatory Filings
2025
Dec 15
Director's Dealing
2025
Dec 12
Director's Dealing
2025
Dec 12
Director's Dealing
2025
Dec 12
Director's Dealing
2025
Dec 12
Director's Dealing
2025
Dec 12